JP2009526024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526024A5 JP2009526024A5 JP2008553777A JP2008553777A JP2009526024A5 JP 2009526024 A5 JP2009526024 A5 JP 2009526024A5 JP 2008553777 A JP2008553777 A JP 2008553777A JP 2008553777 A JP2008553777 A JP 2008553777A JP 2009526024 A5 JP2009526024 A5 JP 2009526024A5
- Authority
- JP
- Japan
- Prior art keywords
- nonane
- alkyl
- diaza
- bicyclo
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 trifluoromethoxy, cyano, hydroxy, amino Chemical group 0.000 claims 12
- 208000002193 Pain Diseases 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- PJDJTXWCVQUXKZ-UHFFFAOYSA-N 3,9-diazabicyclo[3.3.1]nonane Chemical class C1NCC2CCCC1N2 PJDJTXWCVQUXKZ-UHFFFAOYSA-N 0.000 claims 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- KTSZYXNHBVWNNV-UHFFFAOYSA-N 1,2-diazabicyclo[3.3.1]nonane Chemical class C1CNN2CCCC1C2 KTSZYXNHBVWNNV-UHFFFAOYSA-N 0.000 claims 2
- KALQUTMYMITSJY-UHFFFAOYSA-N 1-[6-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)pyridin-2-yl]ethanone Chemical compound CN1C(C2)CCCC1CN2C1=CC=CC(C(C)=O)=N1 KALQUTMYMITSJY-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical class CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims 1
- WZZMQKRYTCKVOB-UHFFFAOYSA-N 3-(3,5-dichloropyridin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound ClC1=CC(Cl)=CN=C1N1CC(N2)CCCC2C1 WZZMQKRYTCKVOB-UHFFFAOYSA-N 0.000 claims 1
- NQLLBYSQVFAMBR-UHFFFAOYSA-N 3-(3,5-dichloropyridin-2-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=NC=C(Cl)C=C1Cl NQLLBYSQVFAMBR-UHFFFAOYSA-N 0.000 claims 1
- FOLYZGHWMULZAL-UHFFFAOYSA-N 3-(5-bromopyridin-2-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=C(Br)C=N1 FOLYZGHWMULZAL-UHFFFAOYSA-N 0.000 claims 1
- WENFNLLAIBNWEV-UHFFFAOYSA-N 3-(5-bromopyrimidin-2-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=NC=C(Br)C=N1 WENFNLLAIBNWEV-UHFFFAOYSA-N 0.000 claims 1
- HMFSWEFOJYSNEA-UHFFFAOYSA-N 3-(5-chloropyridin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound N1=CC(Cl)=CC=C1N1CC(N2)CCCC2C1 HMFSWEFOJYSNEA-UHFFFAOYSA-N 0.000 claims 1
- HSOFLWPVSSPPER-UHFFFAOYSA-N 3-(5-chloropyridin-2-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=C(Cl)C=N1 HSOFLWPVSSPPER-UHFFFAOYSA-N 0.000 claims 1
- MCGBLYBSRPXEMN-UHFFFAOYSA-N 3-(5-chloropyridin-3-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CN=CC(Cl)=C1 MCGBLYBSRPXEMN-UHFFFAOYSA-N 0.000 claims 1
- IFMKGCZBBOQAES-UHFFFAOYSA-N 3-(5-ethenoxypyridin-3-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CN=CC(OC=C)=C1 IFMKGCZBBOQAES-UHFFFAOYSA-N 0.000 claims 1
- FFPIONJFGLJQDS-UHFFFAOYSA-N 3-(5-ethoxypyridin-3-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CCOC1=CN=CC(N2CC3CCCC(N3C)C2)=C1 FFPIONJFGLJQDS-UHFFFAOYSA-N 0.000 claims 1
- JOYILSYQCHDVFR-UHFFFAOYSA-N 3-(5-iodopyridin-2-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=C(I)C=N1 JOYILSYQCHDVFR-UHFFFAOYSA-N 0.000 claims 1
- ZJTKAUSTAJQBFU-UHFFFAOYSA-N 3-(5-methoxypyridin-3-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound COC1=CN=CC(N2CC3CCCC(N3C)C2)=C1 ZJTKAUSTAJQBFU-UHFFFAOYSA-N 0.000 claims 1
- LALFQRDCYLMIPJ-UHFFFAOYSA-N 3-(6-bromopyridazin-3-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=C(Br)N=N1 LALFQRDCYLMIPJ-UHFFFAOYSA-N 0.000 claims 1
- BCSZKVWNNHNNKB-UHFFFAOYSA-N 3-(6-bromopyridin-2-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=CC(Br)=N1 BCSZKVWNNHNNKB-UHFFFAOYSA-N 0.000 claims 1
- GIYKJJMFIDNQOI-UHFFFAOYSA-N 3-(6-bromopyridin-3-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=C(Br)N=C1 GIYKJJMFIDNQOI-UHFFFAOYSA-N 0.000 claims 1
- FKPBUOVSLGHAOV-UHFFFAOYSA-N 3-(6-chloropyridazin-3-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=C(Cl)N=N1 FKPBUOVSLGHAOV-UHFFFAOYSA-N 0.000 claims 1
- DRHRNFOXAZGCRZ-UHFFFAOYSA-N 3-(6-chloropyridin-2-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=CC(Cl)=N1 DRHRNFOXAZGCRZ-UHFFFAOYSA-N 0.000 claims 1
- CWGPISHJMTVJJO-UHFFFAOYSA-N 3-(6-chloropyridin-3-yl)-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=C(Cl)N=C1 CWGPISHJMTVJJO-UHFFFAOYSA-N 0.000 claims 1
- DCJZPFINNZSOKC-UHFFFAOYSA-N 3-pyridin-2-yl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1C(N2)CCCC2CN1C1=CC=CC=N1 DCJZPFINNZSOKC-UHFFFAOYSA-N 0.000 claims 1
- KTQXGSDTHCJPLU-UHFFFAOYSA-N 3-pyridin-3-yl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1C(N2)CCCC2CN1C1=CC=CN=C1 KTQXGSDTHCJPLU-UHFFFAOYSA-N 0.000 claims 1
- AHQBXQMHWUNILM-CLTKARDFSA-N 9-methyl-3-[5-[(z)-prop-1-enoxy]pyridin-3-yl]-3,9-diazabicyclo[3.3.1]nonane Chemical compound C\C=C/OC1=CN=CC(N2CC3CCCC(N3C)C2)=C1 AHQBXQMHWUNILM-CLTKARDFSA-N 0.000 claims 1
- NFUKHWSWHXLNMT-UHFFFAOYSA-N 9-methyl-3-pyridazin-3-yl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=CN=N1 NFUKHWSWHXLNMT-UHFFFAOYSA-N 0.000 claims 1
- KHQNUZUXDBHVNC-UHFFFAOYSA-N 9-methyl-3-pyridin-3-yl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C1=CC=CN=C1 KHQNUZUXDBHVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 230000007074 memory dysfunction Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77189006P | 2006-02-10 | 2006-02-10 | |
| DKPA200600190 | 2006-02-10 | ||
| PCT/EP2007/051272 WO2007090888A1 (en) | 2006-02-10 | 2007-02-09 | 3-heteroaryl- 3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009526024A JP2009526024A (ja) | 2009-07-16 |
| JP2009526024A5 true JP2009526024A5 (enExample) | 2010-04-02 |
Family
ID=38050943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553777A Abandoned JP2009526024A (ja) | 2006-02-10 | 2007-02-09 | ニコチン性アセチルコリン受容体アゴニストとしての３−ヘテロアリール−３，９−ジアザビシクロ［３．３．１］ノナン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7687523B2 (enExample) |
| EP (1) | EP1987031A1 (enExample) |
| JP (1) | JP2009526024A (enExample) |
| AU (1) | AU2007213671A1 (enExample) |
| CA (1) | CA2641685A1 (enExample) |
| WO (1) | WO2007090888A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700596B2 (en) | 2006-02-10 | 2010-04-20 | Neurosearch A/S | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AU2007213670A1 (en) | 2006-02-10 | 2007-08-16 | Neurosearch A/S | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CA2706974A1 (en) * | 2007-11-30 | 2009-06-04 | Neurosearch A/S | Novel carboxylic acid 4-phenylazo-phenyl ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US8148408B2 (en) | 2008-05-09 | 2012-04-03 | Abbott Laboratories | Selective substituted pyridine ligands for neuronal nicotinic receptors |
| US20110142758A1 (en) * | 2008-06-10 | 2011-06-16 | Neurosearch A/S | Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods |
| TW201004963A (en) * | 2008-07-03 | 2010-02-01 | Targacept Inc | Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands |
| US20180311238A1 (en) * | 2017-04-28 | 2018-11-01 | Saniona A/S | Selective Agonist Of a6 Containing nAChRs |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3196154A (en) | 1962-05-17 | 1965-07-20 | Sterling Drug Inc | 3-substituted-9-methyl-3, 9-diazabicyclo [3.3.1] nonanes |
| IN166416B (enExample) | 1985-09-18 | 1990-05-05 | Pfizer | |
| US5478939A (en) | 1994-07-20 | 1995-12-26 | American Cyanamid Company | (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives |
| CN1205210C (zh) | 1997-05-30 | 2005-06-08 | 神经研究公司 | 作为尼古丁ACh受体上胆碱能配体的9－氮杂双环(3.3.1)壬－2－烯衍生物 |
| HUP0002713A3 (en) | 1997-05-30 | 2001-02-28 | Neurosearch As | 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use |
| US7494999B2 (en) | 2004-10-29 | 2009-02-24 | Kalypsys, Inc | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| EP0952154B1 (en) | 1998-04-16 | 2004-08-18 | Pfizer Products Inc. | N-acyl and N-aroyl aralkyl amides |
| FR2786770B1 (fr) | 1998-12-04 | 2001-01-19 | Synthelabo | Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique |
| US7265115B2 (en) | 1999-01-29 | 2007-09-04 | Abbott Laboratories | Diazabicyclic CNS active agents |
| DE60006213T2 (de) | 1999-01-29 | 2004-07-29 | Abbott Laboratories, Abbott Park | Diazabicyloderivate als nikotin-acetylcholin-rezeptorliganden |
| CA2365258A1 (en) | 1999-05-04 | 2000-11-09 | Neurosearch A/S | Heteroaryl diazabicycloalkanes, their preparation and use |
| US6852721B2 (en) | 2000-05-25 | 2005-02-08 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| CN1185233C (zh) | 2000-07-04 | 2005-01-19 | 神经研究公司 | 芳基和杂芳基－二氮杂双环烷烃,其制备和用途 |
| US20040147505A1 (en) | 2001-06-01 | 2004-07-29 | Dan Peters | Novel heteroaryl-diazabicyclo alkanes as cns-modulators |
| US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| MXPA06005019A (es) | 2003-11-03 | 2006-07-06 | Warner Lambert Co | Nuevos inhibidores de la recaptacion de norpinefrina para el tratamiento de transtornos del sistema nervioso central. |
| MX2007004269A (es) | 2004-10-20 | 2007-06-15 | Neurosearch As | Derivados de arilo diazabiciclico nuevos y su uso medico. |
| JP2008530172A (ja) | 2005-02-16 | 2008-08-07 | ノイロサーチ アクティーゼルスカブ | ジアザ二環系アリール誘導体及びそれらのニコチン様アセチルコリン受容体におけるコリン作動性リガンドとしての使用 |
| EP1963323B1 (en) | 2005-12-06 | 2010-07-14 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| US7700596B2 (en) | 2006-02-10 | 2010-04-20 | Neurosearch A/S | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AU2007213670A1 (en) | 2006-02-10 | 2007-08-16 | Neurosearch A/S | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
-
2007
- 2007-02-09 EP EP07704487A patent/EP1987031A1/en not_active Withdrawn
- 2007-02-09 WO PCT/EP2007/051272 patent/WO2007090888A1/en not_active Ceased
- 2007-02-09 CA CA002641685A patent/CA2641685A1/en not_active Abandoned
- 2007-02-09 AU AU2007213671A patent/AU2007213671A1/en not_active Abandoned
- 2007-02-09 US US12/087,004 patent/US7687523B2/en active Active
- 2007-02-09 JP JP2008553777A patent/JP2009526024A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526024A5 (enExample) | ||
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| AU2005284131B2 (en) | Substituted bicyclic imidazo-3-YL-amine compounds | |
| JP2008530172A5 (enExample) | ||
| IL259421A (en) | Modulators of ror-gamma | |
| EP1289996B1 (en) | Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands | |
| JP2009538867A5 (enExample) | ||
| JP2008530171A5 (enExample) | ||
| JP2002535409A (ja) | ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式誘導体 | |
| JP2009538866A5 (enExample) | ||
| WO2006114400A1 (en) | Novel oxadiazole derivatives and their medical use | |
| KR20060125885A (ko) | 콜린 수용체 조절제로서의 디아자바이사이클릭 아릴 유도체 | |
| WO2012167423A1 (en) | Substituted pyridopyrazines as novel syk inhibitors | |
| JP2009538869A5 (enExample) | ||
| JP2009526814A5 (enExample) | ||
| JP2008517032A5 (enExample) | ||
| JP2009537599A5 (enExample) | ||
| JP2007520525A5 (enExample) | ||
| JP2007530635A5 (enExample) | ||
| JP2009526024A (ja) | ニコチン性アセチルコリン受容体アゴニストとしての３−ヘテロアリール−３，９−ジアザビシクロ［３．３．１］ノナン誘導体 | |
| KR101803866B1 (ko) | 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체 | |
| RU2010135037A (ru) | Новые производные, 1,4-диазабицикло[3.2.2]нонилоксадиазолил, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| JP2009537598A5 (enExample) | ||
| JP2009537600A5 (enExample) | ||
| US20080242689A1 (en) | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof |